Form 4: IDEAYA CCO Stuart Dorman Granted 155,000 Stock Options

IDEAYA Biosciences' Chief Commercial Officer, Stuart Dorman, was granted 155,000 stock options with an exercise price of $32.19, vesting over four years.

Summary

• Stuart Dorman, Chief Commercial Officer of IDEAYA Biosciences, Inc. (IDYA), was granted 155,000 stock options.
• The transaction date for this grant was January 30, 2026.
• The exercise price for these stock options is $32.19 per share.
• The options begin vesting on January 1, 2026 (the Vesting Commencement Date).
• 25% of the shares subject to the option will vest on the first anniversary of the Vesting Commencement Date (January 1, 2027).
• Thereafter, 1/48th of the total number of shares will vest monthly.
• 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date (January 1, 2030).
• The expiration date for these stock options is January 30, 2036.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive development, as it aligns the Chief Commercial Officer's incentives with long-term shareholder value creation through equity ownership, without indicating any immediate operational or financial changes.

Positives

• The grant of stock options aligns the Chief Commercial Officer's long-term interests with those of shareholders, incentivizing performance and retention.
• This is a standard form of executive compensation, indicating continued commitment from key management.

Negatives

• The options do not represent immediate ownership and their value is contingent on future stock price appreciation above the exercise price.
• The options are subject to a multi-year vesting schedule, meaning the full benefit is not immediately realized.

Risks

• The value of the stock options is subject to the market price fluctuations of IDEAYA Biosciences' common stock.
• The options will only become valuable if the company's stock price rises above the $32.19 exercise price.
• Vesting conditions must be met for the options to become exercisable, including continued employment.

Future Outlook

This stock option grant is a forward-looking incentive, designed to motivate the Chief Commercial Officer to contribute to the company's long-term growth and increase shareholder value, as the options' value is tied to future stock price appreciation.

Industry Context

StockSavvy.ai notes that equity grants are a common practice in the biotech industry to attract and retain key talent, aligning executive incentives with long-term company performance and shareholder value creation. Such grants are crucial for companies like IDEAYA Biosciences, which rely on specialized expertise for drug development and commercialization.

Comparison to Industry Standards

• StockSavvy.ai observes that a four-year vesting schedule with a one-year cliff (25% after one year, then monthly) is a standard practice for executive stock options in the biotechnology sector.
• This vesting structure is comparable to grants observed at other growth-oriented biotech companies for similar-level executives, aiming to ensure long-term commitment and performance.

Stakeholder Impact

• Shareholders: The grant aims to align management's interests with shareholder value creation, potentially leading to better long-term performance.
• Employees (Stuart Dorman): Receives a significant equity incentive as part of his compensation package, enhancing his potential long-term wealth tied to company success.

Next Steps

• The stock options will vest according to the specified schedule, with the first 25% vesting on January 1, 2027.
• Stuart Dorman may choose to exercise the vested options at any point before their expiration date of January 30, 2036, subject to company policy and blackout periods.

Key Dates

Recommendation

This Form 4 reports a routine executive compensation grant and does not provide new information about the company's operational or financial performance that would alter an investment thesis. It primarily indicates management's continued alignment with shareholder interests, which is generally a positive but not a catalyst for a change in recommendation.

Keywords

IDEAYA Biosciences, IDYA, Stuart Dorman, Stock Option, Executive Compensation, Insider Transaction, Equity Grant, Form 4, Vesting